Arcturus Receives FDA Approval of Phase 2 Vaccine Trials

BIOTECH: Company Moves Forward on One Shot mRNA COVID-19 Vaccine

“If a single shot vaccine is desired, our view is that you need a technology that invokes not only humoral immunity, but cellular immunity is also very important.” JOE PAYNE

„„ ▪ By NATALLIE ROCHA
THE LIST


Arcturus Therapeutics (Nasdaq: ARCT) received approval from the Food and Drug Administration (FDA) to proceed with Phase 2 trials of its COVID-19 vaccine candidate, LUNAR-COV19. The Jan. 4 announcement comes a week after the local biotech company...

Read latest San Diego Business Journal online.

Online newspapers at PressDisplay.